Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMercia Asset Regulatory News (MERC)

Share Price Information for Mercia Asset (MERC)

Share Price is delayed by 15 minutes
Get Live Data
29.50    0.00 (0.00%)
Bid:
29.00
Ask:
30.00
Spread: 1.00 (3.448%)
Market Cap: £124.75m
MERC Live PriceLast checked at - London Stock Exchange

Intraday Mercia Asset Share Chart

Acquisition

7 Sep 2009 07:00

RNS Number : 5982Y
Merchant Securities PLC
07 September 2009
Β 

ο»Ώ

News release

7 SeptemberΒ 2009

Merchant Securities plc

Acquisition of Wealth Management Company

Merchant Securities plc (theΒ "Group"), theΒ financial services groupΒ specialising in private client investment management,Β institutional research and trading,Β corporate financeΒ and corporate brokingΒ announcesΒ that it has entered into an unconditional agreementΒ (the "Agreement")Β to acquire Cavendish Young Limited,Β  ("Cavendish Young")Β anΒ IndependentΒ FinancialΒ AdviserΒ &Β fee based Wealth ManagementΒ  companyΒ based in Belgravia, LondonΒ (the "Acquisition").

Cavendish Young, whichΒ was formed in 1999, managesΒ Β£46Β millionΒ for high net worth individuals and has a total client base ofΒ 2500Β private clients.Β For the year endedΒ 31 March 2009, Cavendish Young made a profit before taxation of Β£2,665Β on turnover of Β£630,342Β and had net assets of Β£229,018Β on that date. The sellers of Cavendish Young are Mark Estcourt, the founder and managing director of the company and his wife TracyΒ Estcourt. Mr Estcourt has entered into aΒ newΒ service agreement with Cavendish Young.Β 

The initial consideration for the Acquisition is Β£65,000, of which Β£32,500 was paid on completion, with the balanceΒ payableΒ following agreement ofΒ theΒ completion balance sheet. Further deferred consideration may become payable dependent upon two factors: the future profitability of CavendishΒ YoungΒ in the financial periods ending 31 March 2014, withΒ aΒ potentialΒ deferred considerationΒ in this regard capped atΒ Β£800,000 and the amount of funds which come under theΒ discretionaryΒ management of the GroupΒ over the same period, with an additional potential deferred considerationΒ capped atΒ Β£500,000, giving a maximum potential total consideration of Β£1.3 million.Β 

As at 31 July 2009 the GroupΒ hadΒ Β£85Β million under advisory management and a further Β£6.5Β millionΒ underΒ discretionary management. The AcquisitionΒ increases the total funds under Group management to over Β£135Β million andΒ has the potential to increase the funds under the Group's discretionary managementΒ toΒ over Β£50Β million, before any future growth.

Patrick Claridge, Chief Executive of Merchant SecuritiesΒ plc, says:

"This acquisitionΒ fits well withΒ our strategy toΒ increase long term recurringΒ income across our three sectors of private client, institutional and corporate finance and corporate broking business.Β This dealΒ representsΒ a major stepΒ forwardΒ for the private client business,Β increasingΒ totalΒ Group funds under advisoryΒ and discretionaryΒ managementΒ to overΒ Β£135Β million. We will continue to seek appropriate ways of expanding the Group, with anΒ emphasis onΒ increasing longΒ term recurring income andΒ delivering a high-qualityΒ service to ourΒ entireΒ client base."

- Ends -Β 

For further information please contact:

Merchant Securities plc

Patrick Claridge (Chief Executive)

Broadgate

Roland Cross/Emma Murphy

Arden Partners plc

Richard Day

020 7375 9010

020 7726 6111

020 7398 1600

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
ACQLIMRTMMIMBIL
Date   Source Headline
5th Jul 201910:00 amRNSChange of Name
2nd Jul 20197:00 amRNSDirectorate Change
21st May 20197:00 amRNS£2.4million syndicated investment into Medherant
15th May 20197:00 amRNS£2.0million syndicated investment into Locate Bio
14th May 20197:06 amRNSConcepta PLC confirms first myLotus® pregnancies
2nd May 20197:00 amRNSNotice of Preliminary Results
11th Apr 20199:41 amRNSPDMR Dealing
10th Apr 20197:00 amRNSDirector/ PDMR Dealings
28th Mar 20197:00 amRNS£6.5m syndicated investment into Oxford Genetics
18th Mar 20194:23 pmRNSPDMR / Director Dealings
15th Mar 20191:19 pmRNSPDMR / Director Dealings
12th Mar 20197:06 amRNSPortfolio company Concepta secures partnership
28th Feb 20197:00 amRNSPortfolio company announces six licensing deals
20th Feb 20197:00 amRNSSoftware & the Internet Portfolio Update
5th Feb 20197:00 amRNSAppointment of NOMAD
3rd Dec 20187:00 amRNSHalf Year Results
31st Oct 20187:00 amRNSNotice of Results
29th Oct 20187:00 amRNSNew Direct Investment in W2 Global Data Solutions
18th Oct 20187:00 amRNSCapital Markets Day
16th Oct 20187:00 amRNSNew Emerging Star investment into Locate Bio
21st Sep 201810:47 amRNSResult of AGM
21st Sep 20187:00 amRNSAGM Statement
18th Sep 20187:00 amRNSAston EyeTech secures multi-million pound contract
13th Sep 20187:00 amRNSNotice of Capital Markets Day
29th Aug 20187:00 amRNSGrant of Options
16th Aug 20187:00 amRNSnDreams secures multi-million dollar contract
7th Aug 20187:00 amRNSOG wins significant multi-million pound contract
27th Jul 20189:30 amRNSPublication of Annual Report
17th Jul 20183:14 pmRNSPDMR / Director Dealings
2nd Jul 20187:00 amRNSPreliminary Results
20th Jun 20187:00 amRNSVirtTrade secures partnership with Formula 1
12th Jun 20187:00 amRNSBoard Appointment
21st May 20187:00 amRNSNotice of Preliminary Results
17th Apr 20187:00 amRNSBoard Change
26th Mar 20187:00 amRNSDeferred Consideration and Board Change
22nd Mar 20187:00 amRNSNew Direct Investment in Voxpopme
2nd Mar 20187:00 amRNSSale of Science Warehouse Limited
1st Feb 20187:00 amRNSMercia Annual Gala Dinner
22nd Dec 20177:00 amRNSBoard Appointment
18th Dec 20177:00 amRNSAmendment to Share Options
13th Dec 20177:00 amRNS£5.0million syndicated investment into Intechnica
11th Dec 20177:00 amRNS£3.8million syndicated investment into Medherant
6th Dec 20177:00 amRNSHalf Year Results
24th Nov 20177:00 amRNSImpression Technologies secures grant funding
17th Nov 20177:00 amRNSNew Direct Investment in £5.0m syndicated round
14th Nov 20177:00 amRNSLife Sciences & Biosciences sector update
1st Nov 20177:00 amRNSNew Partnership with the University of Edinburgh
31st Oct 20177:00 amRNSNotice of Results
25th Oct 20177:00 amRNSAppointment of Joint Broker
5th Oct 20177:00 amRNSFurther significant fund realisation achieved

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.